Michelle Onorato, MD
Infectious Disease · Webster, TXNPI 1417991795
Payments from drug & device makers
Across 481 payments — averaging $17.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$2K
- Viiv Healthcare Company$1K
- AbbVie$792
- Insmed, Inc.$547
- Merck$422
- Melinta Therapeutics, LLC$392
- plus $3K from 32 others
What the payments were for
- Food & beverage$8,47499%
- Education$1021%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 122 | $2,146 |
| Viiv Healthcare Company | 93 | $1,391 |
| AbbVie(2 entities) | 40 | $792 |
| Insmed, Inc. | 24 | $547 |
| Merck | 24 | $422 |
| Melinta Therapeutics, LLC | 21 | $392 |
| Amgen | 20 | $331 |
| Johnson & Johnson(2 entities) | 18 | $312 |
| Shionogi Inc | 14 | $294 |
| Theratechnologies Inc. | 11 | $282 |
| Sanofi-aventis U.S. LLC | 14 | $228 |
| EMD Serono, Inc. | 11 | $188 |
| Amarin Pharma, Inc. | 10 | $186 |
| Paratek Pharmaceuticals, Inc. | 8 | $161 |
| Arbor Pharmaceuticals, Inc. | 10 | $123 |
| Aimmune Therapeutics, Inc. | 4 | $92 |
| Boehringer Ingelheim | 4 | $62 |
| Bayer | 3 | $56 |
| Boston Scientific | 3 | $54 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| Astellas Pharma US Inc | 2 | $44 |
| Ferring Pharmaceuticals Inc. | 2 | $43 |
| Napo Pharmaceuticals Inc | 2 | $36 |
| Aytu Biopharma, Inc. | 2 | $36 |
| Novartis | 2 | $35 |
| Edwards Lifesciences | 1 | $35 |
| Smith+Nephew | 2 | $34 |
| La Jolla Pharmaceutical Company | 1 | $34 |
| Cardiovascular Systems Inc. | 1 | $26 |
| KCI USA, Inc. | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $17 |
| Inari Medical, Inc. | 1 | $17 |
| AstraZeneca | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Integra Lifesciences Corporation | 1 | $14 |
| Vyera Pharmaceuticals, LLC | 1 | $13 |
| Kerecis Limited | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Descovy$124
How this compares
$8,576 in reported general payments places this provider in the 80th percentile of 576 infectious disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 178 | $807,754 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 74 | $345,171 |
| SerostimSomatropin | 16 | $332,086 |
| DovatoDolutegravir Sodium/Lamivudine | 84 | $251,792 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 56 | $237,047 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 51 | $183,444 |
| Egrifta SvTesamorelin Acetate | 15 | $167,862 |
| CabenuvaCabotegravir/Rilpivirine | 18 | $109,990 |
| TivicayDolutegravir Sodium | 42 | $93,175 |
| JulucaDolutegravir/Rilpivirine | 23 | $77,261 |
| DescovyEmtricitabine/Tenofov Alafenam | 21 | $48,767 |
| ErtapenemErtapenem Sodium | 38 | $16,328 |
| Fosfomycin Tromethamine | 69 | $11,313 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 38 | $8,394 |
| Meropenem | 21 | $4,253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy, Genvoya, Descovy | $2,146 | $1,201,692273 claims |
| Viiv Healthcare CompanyDovato, Triumeq, Cabenuva, Tivicay, Juluca | $1,391 | $769,266223 claims |
| EMD Serono, Inc.Serostim | $188 | $332,08616 claims |
| Theratechnologies Inc.Egrifta Sv | $282 | $167,86215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 576 infectious disease providers in Texas.
Other infectious disease in Webster
- Husam IssaWebster$460K
- Gene VoskuhlSherman$69.5M
- Mezgebe BerheDallas$11M
- Eleftherios MylonakisHouston$6.4M
- Mamta JainDallas$3.7M
- Cheryl McDonaldFort Worth$3.1M
- Ogechika AlozieEl Paso$2.5M
- Roberto ArduinoHouston$2.1M
- Issam RaadHouston$2M
- Joseph GatheHouston$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.